Naoto Shikama
Papers
1
Total Citations
7
H-Index
1
About
Naoto Shikama is a leading figure in radiation oncology, with a focused expertise in stereotactic body radiotherapy (SBRT) and the management of genitourinary malignancies. His research is centered on optimizing treatment precision while minimizing toxicity, particularly through the use of advanced non-isocentric robotic radiosurgery systems. Shikama’s major contribution lies in pioneering the clinical application of extremely hypofractionated radiotherapy (EHF-RT) for early-stage prostate cancer. His seminal 2016 feasibility study, which has garnered 7 citations, provided critical early evidence that delivering ultra-high doses per fraction with robotic precision is both safe and effective, specifically characterizing the low rates of rectal toxicity in low-to-intermediate risk patients. This work helped lay the groundwork for the modern shift toward shorter, more convenient treatment courses. Beyond prostate cancer, Shikama’s broader impact is reflected in his extensive publication record on SBRT for various tumor sites, contributing to international guidelines. His dedication to balancing tumor control with quality of life continues to influence clinical practice and inspire a new generation of radiation oncologists.
Research Focus
Key Achievements
Top Papers
- 1